Navigating New Waters in HER2+ mCRC: Selection of the Optimal Targeted Regimen, a Case-Based Approach

Advancing the Standard of Care in HER2 Positive mCRC: The Role of Tyrosine Kinase Inhibitors

Navigating New Waters in HER2+ mCRC: Selection of the Optimal Targeted Regimen, a Case-Based Approach

ReachMD Healthcare Image
Media formats available:
  • Overview

    This program explores treatment options for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic colorectal cancer (mCRC). To make informed decisions when treating patients with HER2-positive status, clinicians must understand using HER2 as a testing target and know the latest treatment options available. This activity raises clinician awareness of the impact of testing for HER2 status in patients with mCRC and of identifying patients with CRC who would benefit from HER2-directed therapies.

  • Target Audience

    This activity has been designed to meet the educational needs of the interprofessional team, including community oncologists, oncology nurses, pathologists, gastroenterologists, as well as other clinicians involved in the management of patients with colorectal cancer.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Apply appropriate diagnostic methods to identify patients with mCRC who are candidates for HER2-directed therapy
    • Differentiate between HER2-targeted tyrosine kinase inhibitors based on downstream effects of target specificity
    • Evaluate efficacy and safety of current treatment options to inform treatment strategies for patients with HER2-positive mCRC
    • Utilize understanding of target profiles, efficacy, and safety considerations to select optimal HER2-targeted TKI combination regimens for a patient with HER2-positive mCRC
  • Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and TotalCME, Inc. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.


    This activity was planned by and for the healthcare team, and learners will receive 1.0  Interprofessional Continuing Education (IPCE) credit(s) for learning and change.

  • Faculty Disclosure of Commercial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs. 

    The following faculty have disclosed:

    John H. Strickler, MD, faculty for this educational event, is a contracted researcher for Abbvie, Amgen, AStar D3, Bayer, Curegenix, Daiichi-Sankyo, Eli Lilly, Erasca, Gossamer Bio, Leap Therapeutics, Nektar, Roche/ Genentech, Sanofi, Seagen, and Silverback Therapeutics; and receives consulting fees from Abbvie, Amgen, AstraZeneca, Bayer, Beigene, Daiichi-Sankyo, Eli Lilly, GSK, Natera, Pfizer, Pionyr Immunotherapeutics, Seagen, Silverback Therapeutics, Takeda, and Viatris. 

    Andrea Cercek, MD, faculty for this educational event,  is a contracted researcher for GSK, and Seagen; currently has patents pending for HAI FUDR in DPD deficiency and Neoadjuvant PD1 in locally adv dMMR solid tumors; and receives consulting fees from Seagen, Merck, Bayer, GSK, and Pfizer. 

  • Planners and Managers Disclosure List

    The following planners/reviewers/managers have disclosed:

    Megan Reimann, PharmD, BCOP, planner for this educational event, has no relevant financial relationships with ineligible companies.

    William Mencia, MD, FACEHP, CHCP, reviewer for this educational event, has no relevant financial relationships with ineligible companies.

    TotalCME, Inc. planners and managers have no relevant commercial relationships to disclose.

    All the relevant financial relationships for these individuals have been mitigated.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME, Inc. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restrictions, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • Acknowledgment

    This activity is supported by an independent educational grant from Seagen.

    Jointly provided by Global Learning Collaborative (GLC) and TotalCME, Inc.

  • Fee Statement

    This activity is FREE to all participants.

  • Instructions for Completion

    During the period 3/20/2023 through 3/20/2024, registered participants wishing to receive continuing education credit for this activity must follow these steps:

    1. Read the learning objectives and faculty disclosures.
    2. Answer a pre-program question.
    3. View the program.
    4. Complete the post-test with a score of 100%.
    5. Complete activity evaluation.
    6. Apply for credit and either bank your credits or print your certificate.

    For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments



We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free